

A Case Report of a Patient Carrying *CYP2C9**3/*4 Genotype with Extremely Low Warfarin Dose Requirement

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with *CYP2C9**3/*4. A 73-yr-old woman with atrial fibrillation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for *CYP2C9* revealed that this patient had a genotype *CYP2C9**3/*4. This is the first Korean compound heterozygote for *CYP2C9**3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

Key Words : Warfarin; Cytochrome P-450 *CYP2C9*; Polymorphism; Prothrombin Time; Pharmacogenetics

Soo-Youn Lee, Myung-Hyun Nam,
June Soo Kim*, Jong-Won Kim

Department of Laboratory Medicine and Internal
Medicine*, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea

Received : 21 November 2005

Accepted : 3 February 2006

Address for correspondence

Jong-Won Kim, M.D.

Department of Laboratory Medicine, Samsung
Medical Center, 50 Irwon-dong, Gangnam-gu, Seoul
135-710, Korea

Tel : +82.2-3410-3414, Fax : +82.2-3410-2719

E-mail : jwonk@smc.samsung.co.kr

*This study was supported by a grant of the Korea
Health 21 R&D Project, Ministry of Health & Welfare,
R. O. K (03-PJ10-PG13-GD01-0002).

INTRODUCTION

Warfarin therapy is problematic due to a narrow therapeutic index and frequent bleeding complications (1-5). Due to the significant interpatient variability for warfarin sensitivity, estimation of the optimal warfarin dose for each patient is difficult. The prolongation of the prothrombin time (PT) remains the primary way to measure the anticoagulant effect of warfarin. Therapy is individualized by monitoring patient's international normalized ratio (INR) of PT.

Warfarin metabolism is catalyzed by *CYP2C9*, which metabolizes S-warfarin to inactive S-7-hydroxywarfarin (4). A genetic polymorphism of *CYP2C9* contributes to the variability among patients for the required maintenance doses of warfarin (4). Multiple studies have clearly demonstrated an increased frequency of *CYP2C9* allelic variants such as *CYP2C9**2 and *CYP2C9**3 in patients stabilized on low-dose warfarin therapy. A relationship has been established between genetic deficiency of the *CYP2C9* enzyme activity and increased likelihood of extremely elevated INRs and major bleeding events, compared to the general population (6-11).

In this report, we present a case of warfarin therapy in a patient with the genotype *CYP2C9**3/*4, which resulted in decreased activity of *CYP2C9*. Prolonged PT during the

induction phase of standard warfarin therapy was found and a marked reduction of warfarin dosage was required to get to the target INR in this case.

CASE REPORT

A 73-yr-old woman with atrial fibrillation presented to the emergency room complaining of chest discomfort, dyspnea, and agitation. The patient had suffered from atrial fibrillation for the last 2 yr. Her medications for the previous 2 yr included diltiazem 90 mg, metoprolol 25 mg, and aspirin 100 mg twice a day. In addition, she had been taking mirzapine 30 mg, alprazolam 0.25 mg, and zolpidem 10 mg daily for a 6 yr history of dysthymia.

Physical examination showed a blood pressure of 100/83 mmHg, a heart rate of 100 beats/min, and a normal body temperature. Her body weight was 62.3 kg, and she was 158 cm in height. Initial laboratory results were unremarkable with a normal PT of 12.3 sec (INR 1.0). Routine chemical studies indicated normal values for total protein (6.6 g/dL), albumin (3.9 g/dL), aspartate aminotransferase (17 U/L), alanine aminotransferase (10 U/L), alkaline phosphatase (79 U/L), total bilirubin (0.3 mg/dL) blood urea nitrogen (16.4 mg/dL), creatinine (0.6 mg/dL), and electrolytes. Results of hema-




Fig. 1. Detection of nucleotide changes by sequencing analysis of *CYP2C9* gene in the patient with *CYP2C9**3/*4 showing A1075C (Ile359Leu) and A1076T (Ile359Thr) substitutions (indicated by arrows).

tological studies including complete blood counts were also normal. Mild cardiomegaly was found on the chest radiography. Electrocardiogram showed atrial fibrillation. Echocardiogram revealed mild aortic, mitral, and tricuspid regurgitation and left atrial enlargement (45 mm).

The patient underwent heparinization with an initial bolus administration of 3,600 IU heparin followed by continuous infusion for 6 days. Then the patient was started on 2 or 3 mg of warfarin daily (16.3 mg/week) to prevent thromboembolism, and was discharged after 3 days with a PT of 37.4 sec (INR 2.81). When she revisited the outpatient clinic after 3 days, her PT was found to be 50.0 sec (INR 3.68). After normalization of the patient's PT with warfarin withdrawal for 3 days, 1 or 2 mg/day (10.5 mg/week) of warfarin was prescribed. The PT after 3 days of treatment was 41.6 sec (INR 3.11). The administration of warfarin dose was changed (6.5-10.5 mg/week) continuously, which resulted in a PT of 20.9-43.1 sec (INR 1.64-3.21). She had to discontinue warfarin therapy temporarily 3 times. The difficulty in finding the optimal treatment dose during the induction period of anticoagulation continued for more than 2 month.

The patient continues to receive warfarin therapy at the outpatient clinic monthly and her PT remains within the recommended target therapeutic range (INR 2.0-3.0), even though her warfarin dose has been reduced to 6.5 mg/week.

The patient was genotyped for *CYP2C9* after informed consent. DNA was isolated from peripheral blood, and all 9 exons of the *CYP2C9* gene were amplified by PCR (11-13). The PCR products were sequenced using the ABI PRISM BigDye terminator Cycle sequencing kit and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, U.S.A.). The patient was found to be an intermediate metabolizer with the genotype of *CYP2C9**3/*4 (Fig. 1).

DISCUSSION

Genetic polymorphisms of *CYP2C9* bring about a significant variability among individuals in regard to drug response (1-4). Patients with genetic variants of *CYP2C9* are very sensitive to warfarin, and may become overanticoagulated on a standard dose.

More than 20 variant alleles of *CYP2C9* have been reported (14). Previous studies have demonstrated that 2 common variants *CYP2C9**2 and *CYP2C9**3 are associated with a reduced catalytic activity of *CYP2C9* (1-11). Therefore, subjects who are homo- or heterozygous for these variant alleles require reduced maintenance doses for *CYP2C9* substrates such as warfarin. Allele frequencies of *CYP2C9* variants have been shown to be markedly different among populations. Caucasians possess higher frequencies of *CYP2C9**3 than Asians (6-10% vs. 2-5%) (1-3). There have been no documented Asian carriers of the *CYP2C9**2 variant, while 8-20% of Caucasians appear to have the *CYP2C9**2 allele (1-11). Yoon *et al.* reported that from a pool of 574 Koreans 2.3% were heterozygous for *CYP2C9**3 and none were found to be carriers of *CYP2C9**2 (15). Caucasian and Asian patients require different warfarin dosages to achieve therapeutic anticoagulation and Asians appear to be more sensitive to warfarin (2, 9). This can only be partly explained by the 2 most common variant alleles of *CYP2C9* in Caucasians, and there is a possibility that unknown *CYP2C9* alleles exist in Asians.

This is the first report of a Korean patient with the *CYP2C9**3/*4 showing warfarin intolerance. The *CYP2C9**4 allele including 1076T>C (Ile359Thr) has been reported in only one Japanese subject (16). However, *CYP2C9* variants other than *CYP2C9**2 and *CYP2C9**3 have not been studied in the Korean population. In addition, there has been no reported Korean subject identified as a compound heterozygote for the 2 variant alleles of *CYP2C9*.

The functional significance of the *CYP2C9**4 allele remains unclear. However, it is assumed that this allele causes significant reduction in the *CYP2C9* enzyme activity. It is known that *CYP2C9**3, *4, and *5 alleles all lie in a putative substrate recognition site, thus providing an explanation for their effects on the K_m for *CYP2C9* substrates (17). The position of 1076T>C (Ile359Thr) substitution is just close to 1075A>C (Ile359Leu) in *CYP2C9**3, which causes decreased enzyme activity. Therefore, 1076T>C (Ile359Thr) in *CYP2C9**4 is likely to affect the enzyme activity as 1075A>C (Ile359Leu) in *CYP2C9**3 (16). While the usual maintenance dose of warfarin is 4-6 mg/day in most patients (28-42 mg/week), our patient required extremely low doses of warfarin (0.5 or 1 mg/day, 6.5 mg/week) to meet the target INR, suggesting a poor metabolizer phenotype with 2 functionally deficient alleles, rather than an intermediate metabolizer phenotype with 1 deficient allele. Gage *et al.* reported that homozygotes for *CYP2C9**3 or compound heterozygotes of *CYP2C9**3 and *CYP2C9**2 had an average daily maintenance warfarin dose of 1.5 mg and 2.0 mg, respectively, compared to a daily maintenance dose of 5.1 mg in wildtype (18).

According to the Korean study of Lee *et al.* (5), 83 patients visited emergency center for 2 yr due to the bleeding complications or high INR related to warfarin therapy. Lee *et al.* reported that one of the main reasons for non-therapeutic

INRs was inadequate dosage adjustment (19) and suggested a dosing guideline for Korean outpatients with prosthetic heart valves (20). However, the current warfarin dosing algorithms still do not incorporate genetic factors that could affect warfarin dose requirements.

Our patient attained a high INR at standard doses and might be at a higher risk for developing severe complications. In this patient, we could not identify any specific pharmacokinetic or pharmacodynamic factors associated with the warfarin response, such as drug interactions or underlying disease conditions. Therefore, a pharmacogenetic test was performed to explore the possible genetic factors contributing to the unusual warfarin response. This patient could have taken appropriate therapeutic measures earlier, and be maintained on a safer regimen with lower doses, if she had been genotyped at the beginning of warfarin therapy.

The CYP2C9 genotype is associated with a risk of over-anticoagulation and bleeding complications. Previous studies have suggested that a variant group, compared with patients with the wild-type genotype, require a higher rate of above-range INR, longer time to reach a therapeutic INR, smaller maintenance doses, longer time to stable warfarin dosing, longer hospitalization, and a higher risk of serious bleeding events (1-4, 6, 7, 11).

CYP2C9 genotyping is recommended to complement PT monitoring especially when unusual metabolic activity of warfarin is suspected. Moreover, CYP2C9 genotyping before the initiation of therapy may serve as an important guide for more rapid dosage adjustment and prediction of drug response in each individual in the future.

REFERENCES

- Kirchheiner J, Brockmoller J. *Clinical consequences of cytochrome P450 2C9 polymorphisms*. *Clin Pharmacol Ther* 2005; 77: 1-16.
- Takahashi H, Echizen H. *Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin*. *Pharmacogenomics J* 2003; 3: 202-14.
- Takahashi H, Echizen H. *Pharmacogenetics of warfarin elimination and its clinical implications*. *Clin Pharmacokinet* 2001; 40: 587-603.
- Aithal GP, Day CP, Kesteven PJ, Daly AK. *Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications*. *Lancet* 1999; 353: 717-9.
- Lee JH, Park JS, Chung SW, Sohn DK, Kim SH, Lee HS. *Warfarin toxicity patients in the Emergency Department*. *J Korean Soc Emerg Med* 2003; 14: 145-9.
- Daly AK, King BP. *Pharmacogenetics of oral anticoagulants*. *Pharmacogenetics* 2003; 13: 247-52.
- Higahi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FL, Rettie AE. *Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy*. *JAMA* 2002; 287: 1690-8.
- Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. *The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin*. *J Am Coll Surg* 2002; 194: 267-73.
- Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H. *Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*. *Clin Pharmacol Ther* 1998; 63: 519-28.
- Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padriani R. *Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance*. *Clin Pharmacol Ther* 2002; 72: 702-10.
- Lee CR, Goldstein JA, Pieper JA. *Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data*. *Pharmacogenetics* 2002; 12: 251-63.
- Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. *Genetic analysis of the human cytochrome P450 CYP2C9 locus*. *Pharmacogenetics* 1996; 6: 429-39.
- Bhasker CR, Miners JO, Coulter S, Birkett DJ. *Allelic and functional variability of cytochrome P4502C9*. *Pharmacogenetics* 1997; 7: 51-8.
- Ingelman-Sunberg M, Nebert DW, Daly AK. *Human cytochrome P450 (CYP) genes*. Available from: URL: <http://www.imm.ki.se/CYPalleles/cyp2c9.htm> (Accession date. 11/25/2005).
- Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha JJ, Shin JG. *Frequency of cytochrome P450 2C9 mutant alleles in a Korean population*. *Br J Clin Pharmacol* 2001; 51: 277-80.
- Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K, Higuchi S. *Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus*. *Pharmacogenetics* 2000; 10: 85-9.
- Voorra D, McLeod HL, Eby C, Gage BF. *Use of pharmacogenetics to guide warfarin therapy*. *Drugs Today* 2004; 40: 247-57.
- Gage BF, Eby C, Milligan PE, Banet GA, Ducan JR, McLeod HL. *Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin*. *Thromb Haemost* 2004; 91: 87-94.
- Lee BK, Lee JY, Jeong YM, Lee MK, Kim KB, Ahn H. *Analysis of factors affecting nontherapeutic INRs in Korean outpatients with mechanical heart valves*. *Korean J Thorac Cardiovasc Surg* 2005; 38: 746-60.
- Lee BK, Lee JY, Jeong YM, Lee MK, Kim KB, Ahn H. *Determination of practical dosing of warfarin in Korean outpatients with mechanical heart valves*. *Korean J Thorac Cardiovasc Surg* 2005; 38: 761-72.